[vc_column width=”2/3″][vc_column_text]
Immune checkpoint modulation in renal cell carcinoma
In this paper, Bedke and colleague highlight the way that patients treated for the metastatic disease in renal cell carcinoma (mRCC) by a cytokine treatment (cytokine Il-2 and IFN-α alone or combine with 5-Fluoracil) have experienced a disease stabilization or remission in up of 30% of the patients. But only for some months. It is a limited therapy due to the increase of regulatory T cells (Tregs) and decreasing of circulating myeloid and plasmacytoid dendritic cells. In this paper, the authors highlight a new way to address renal cell carcinoma treatment targetting immune checkpoint modulation (PD-1, CTLA-4,…). They review the ongoing clinical data linked to the use of such immune checkpoint modulation pathway in the renal carcinoma.
[/vc_column_text][/vc_column][vc_column width=”1/3″][vc_column_text el_class=”centered_button”]
[/vc_column_text][vc_column_text]
Check Point modulator validation system
dedicated system to cell-cell interactions follow-up
[/vc_column_text][vc_button label=”Contact Us” target=”_self” size=”small” style=”light” url=”https://www.cherrybiotech.com/?p=15999″ el_class=”centered_button”][vc_separator height_2=”0″ height=”50″ show_border=”no_border”][/vc_column][vc_column width=”2/3″][vc_column_text]
Summary | The introduction of targeted therapies like the tyrosine kinase (TKI) and mammalian target of rapamycin (mTOR) inhibitors has improved patients survival in general. Nevertheless, the prognosis remains limited. Therapies with a new mode of action are urgently warranted, especially those who would provoke long-term responders or long-lasting complete remissions as observed with unspecific immunotherapy with the cytokines interleukin-2 and interferon-a. In the recent years, a deeper understanding of the underlying immunology of T cell activation led to the development of checkpoint inhibitors, which are mainly monoclonal antibodies and which enhances the presence of the co-stimulatory signals needed for T cell activation or priming. This review discusses the clinical data and ongoing studies available for the inhibition of the PD-1 (CD279) and CTLA-4 (CD152) axis in mRCC. In addition, potential future immunological targets are discussed. This approach of T-cell activation or re-activation by immunological checkpoint inhibition holds the inherent promise to directly affect the tumor cell and thereby to potentially cure a subset of patients with mRCC.
LEARN MORE | Bedke et al. Hum. Vaccines Immunother, 2015[/vc_column_text][/vc_column][vc_column width=”1/3″][vc_column_text]
[/vc_column_text][/vc_column][vc_column width=”1/1″][vc_separator height_2=”0″ height=”50″ show_border=”no_border”][vc_column_text]
[wpspw_post design=”design-1″ post category=”230,231″ show_category_name=”false” show_author=”false” show_tags=”false” limit=”4″ grid=”4″]
[/vc_column_text][/vc_column][vc_column width=”1/1″][vc_separator height_2=”0″ height=”50″ show_border=”no_border”][vc_row_inner][vc_column_inner width=”1/2″][vc_column_text]
[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/2″][vc_separator height_2=”0″ height=”50″ show_border=”no_border”][vc_column_text]
Discover our Check Point modulator validation system
Save biopsies, improve result quality and reduce false positive and negative
[/vc_column_text][vc_button label=”Contact Us” target=”_self” size=”medium” style=”light” url=”https://www.cherrybiotech.com/?p=15999″ el_class=”centered_button”][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/4″][vc_column_inner width=”1/1″]
[/vc_column_inner][/vc_column]